Efficacy and safety of GLP-1 receptor agonists in Parkinson’s disease- a systematic review
A recent study examines the use of GLP-1RAs in Parkinson's disease, finding no significant motor benefits but some improvement in quality of life.
Cannabinoids and cognition in Parkinson’s disease: Insights from animal models and emerging clinical evidence.
Parkinson's disease (PD) is a progressive, multisystem neurodegenerative disorder characterized not only by motor impairments but also by a broad spectrum of...
New Report Shows Parkinson’s Costs Surpass $82 Billion in US in 2024
The economic burden Parkinsons disease imposes in 2024 exceeds $82 billion in the US. This figure underscores the urgent need for cost-effective therapeutic interventions. Cannabis medicine shows emerging evidence for managing motor and non-motor…
Fecal Transplants and the Gut Microbiome in Early Parkinson’s Disease
Emerging research on gut microbiome Parkinsons disease suggests fecal transplants may improve motor symptoms in early Parkinson’s. This study supports the gut-brain axis role in neurodegeneration. Understanding this connection could lead to novel…
Cell Therapy Eases Parkinson’s Motor Symptoms in Early Trial
Cell therapy Parkinsons disease trials offer new hope for easing motor symptoms. Early-phase research suggests potential benefits in neurodegeneration treatment. Understanding these advances is crucial for clinicians and patients.
Survey of 47 Trials Maps Cannabinoid Research in Neurology—But Evidence Gaps Remain Large
This review maps cannabinoid clinical trials neurology, highlighting 47 completed studies focused on conditions such as Multiple Sclerosis and Fibromyalgia. It reveals significant evidence gaps due to non-standardized protocols and outcome measures. The…
Radical Revelations: Nitrosative Stress and the Endocannabinoid System in Age-Related Disorders
This endocannabinoid system neurodegeneration research review highlights the critical role of ECS in modulating nitrosative stress pathways. Emerging evidence suggests ECS modulation may influence neuroinflammation and progression of age-related…
New Funding to Support SER-252 Trial in Advanced Parkinson’s
The synthetic cannabinoid Parkinsons trial SER-252 targets levodopa-induced dyskinesia in advanced Parkinson's disease. This novel therapeutic approach could improve management of motor symptoms. Ongoing research aims to validate its clinical efficacy…
Mapping the Clinical Trial Landscape for Cannabinoids in Neurology: A Registry-Based Systematic Review
This systematic review of cannabinoid clinical trials neurological disorders highlights research focused on Multiple Sclerosis, Fibromyalgia, and Parkinson's Disease. It reveals challenges due to inconsistent protocols and dosing across studies. The…
Pirepemat Shows Promise in Trial for Reducing Risk of Falls in Parkinson’s
The pirepemat trial reducing fall risk in Parkinson's disease shows promising results. Falls are a major concern for Parkinson's patients, and this novel therapeutic offers hope. Further research is needed to confirm efficacy and safety.